JP2022160479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022160479A5 JP2022160479A5 JP2022115252A JP2022115252A JP2022160479A5 JP 2022160479 A5 JP2022160479 A5 JP 2022160479A5 JP 2022115252 A JP2022115252 A JP 2022115252A JP 2022115252 A JP2022115252 A JP 2022115252A JP 2022160479 A5 JP2022160479 A5 JP 2022160479A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antigen
- binding fragment
- heavy chain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000013603 viral vector Substances 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 claims 1
- 102000000503 Collagen Type II Human genes 0.000 claims 1
- 108010041390 Collagen Type II Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 208000004221 Multiple Trauma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125608A JP2024160274A (ja) | 2018-12-13 | 2024-08-01 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779102P | 2018-12-13 | 2018-12-13 | |
| US62/779,102 | 2018-12-13 | ||
| JP2021533300A JP7110491B2 (ja) | 2018-12-13 | 2019-12-13 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
| PCT/IB2019/060802 WO2020121282A1 (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533300A Division JP7110491B2 (ja) | 2018-12-13 | 2019-12-13 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125608A Division JP2024160274A (ja) | 2018-12-13 | 2024-08-01 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022160479A JP2022160479A (ja) | 2022-10-19 |
| JP2022160479A5 true JP2022160479A5 (https=) | 2023-02-10 |
| JP7611191B2 JP7611191B2 (ja) | 2025-01-09 |
Family
ID=69143627
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533300A Active JP7110491B2 (ja) | 2018-12-13 | 2019-12-13 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
| JP2022115252A Active JP7611191B2 (ja) | 2018-12-13 | 2022-07-20 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
| JP2024125608A Pending JP2024160274A (ja) | 2018-12-13 | 2024-08-01 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533300A Active JP7110491B2 (ja) | 2018-12-13 | 2019-12-13 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125608A Pending JP2024160274A (ja) | 2018-12-13 | 2024-08-01 | ヒト補体因子ｃ２ｂに対する抗体及び使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11161900B2 (https=) |
| EP (2) | EP4375297A3 (https=) |
| JP (3) | JP7110491B2 (https=) |
| KR (2) | KR102774146B1 (https=) |
| CN (2) | CN119371526A (https=) |
| AU (3) | AU2019397614B2 (https=) |
| BR (1) | BR112021011107A2 (https=) |
| CA (1) | CA3119655A1 (https=) |
| DK (1) | DK3893924T3 (https=) |
| EA (1) | EA202191658A1 (https=) |
| ES (1) | ES2991894T3 (https=) |
| FI (1) | FI3893924T3 (https=) |
| HU (1) | HUE068993T2 (https=) |
| IL (2) | IL319975A (https=) |
| LT (1) | LT3893924T (https=) |
| MX (2) | MX2021006864A (https=) |
| PL (1) | PL3893924T3 (https=) |
| PT (1) | PT3893924T (https=) |
| SG (1) | SG11202105195PA (https=) |
| WO (1) | WO2020121282A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020121282A1 (en) * | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
| WO2025260123A1 (en) * | 2024-06-17 | 2025-12-26 | CSL Innovation Pty Ltd | Anti-c2 antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| SG10201608871XA (en) | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US9815890B2 (en) * | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| CN105968209B (zh) * | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN110229216B (zh) | 2011-09-07 | 2023-06-16 | 宾夕法尼亚州大学理事会 | 具有改善的药代动力学性质的坎普他汀类肽 |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| CN105492461B (zh) | 2013-05-23 | 2019-11-26 | 布罗泰欧制药有限公司 | 结合人类补体因子c2的结合分子及其应用 |
| CA2859114A1 (en) | 2013-08-29 | 2015-02-28 | International Automotive Components Group North America, Inc. | Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof |
| EP3733244A1 (en) | 2013-10-02 | 2020-11-04 | Medlmmune, LLC | Neutralizing anti-influenza a antibodies and uses thereof |
| SMT202000659T1 (it) * | 2013-10-17 | 2021-01-05 | Omeros Corp | Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| HUE070383T2 (hu) | 2014-11-05 | 2025-06-28 | Annexon Inc | Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik |
| MX2018006249A (es) | 2015-11-19 | 2018-11-09 | Abbvie Stemcentrx Llc | Nuevos anticuerpos anti-emr2 y metodos de uso. |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| EP3408279A1 (en) | 2016-01-27 | 2018-12-05 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
| EP3454902A4 (en) | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| WO2018107109A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CA3055781A1 (en) | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2019
- 2019-12-13 WO PCT/IB2019/060802 patent/WO2020121282A1/en not_active Ceased
- 2019-12-13 SG SG11202105195PA patent/SG11202105195PA/en unknown
- 2019-12-13 LT LTEPPCT/IB2019/060802T patent/LT3893924T/lt unknown
- 2019-12-13 PT PT198327371T patent/PT3893924T/pt unknown
- 2019-12-13 CN CN202411410387.8A patent/CN119371526A/zh active Pending
- 2019-12-13 AU AU2019397614A patent/AU2019397614B2/en active Active
- 2019-12-13 MX MX2021006864A patent/MX2021006864A/es unknown
- 2019-12-13 FI FIEP19832737.1T patent/FI3893924T3/fi active
- 2019-12-13 IL IL319975A patent/IL319975A/en unknown
- 2019-12-13 JP JP2021533300A patent/JP7110491B2/ja active Active
- 2019-12-13 IL IL283916A patent/IL283916B2/en unknown
- 2019-12-13 HU HUE19832737A patent/HUE068993T2/hu unknown
- 2019-12-13 DK DK19832737.1T patent/DK3893924T3/da active
- 2019-12-13 BR BR112021011107A patent/BR112021011107A2/pt unknown
- 2019-12-13 EP EP24164880.7A patent/EP4375297A3/en active Pending
- 2019-12-13 PL PL19832737.1T patent/PL3893924T3/pl unknown
- 2019-12-13 EP EP19832737.1A patent/EP3893924B1/en active Active
- 2019-12-13 CA CA3119655A patent/CA3119655A1/en active Pending
- 2019-12-13 EA EA202191658A patent/EA202191658A1/ru unknown
- 2019-12-13 US US16/714,264 patent/US11161900B2/en active Active
- 2019-12-13 KR KR1020217021353A patent/KR102774146B1/ko active Active
- 2019-12-13 ES ES19832737T patent/ES2991894T3/es active Active
- 2019-12-13 KR KR1020257005663A patent/KR20250030005A/ko active Pending
- 2019-12-13 CN CN201980082826.8A patent/CN113260375B/zh active Active
-
2021
- 2021-06-10 MX MX2025010337A patent/MX2025010337A/es unknown
- 2021-10-01 US US17/491,656 patent/US11591386B2/en active Active
-
2022
- 2022-01-10 US US17/572,518 patent/US11708403B2/en active Active
- 2022-07-20 JP JP2022115252A patent/JP7611191B2/ja active Active
- 2022-12-15 AU AU2022287637A patent/AU2022287637B2/en active Active
-
2023
- 2023-06-07 US US18/330,903 patent/US20240002484A1/en active Pending
-
2024
- 2024-08-01 JP JP2024125608A patent/JP2024160274A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252632A patent/AU2025252632A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022160479A5 (https=) | ||
| KR101956059B1 (ko) | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 | |
| WO2012007495A1 (en) | Antibodies specifically binding to human tslpr and methods of use | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| EP2625200A1 (en) | Antibodies against human tweak and uses thereof | |
| FI3893924T3 (fi) | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja | |
| IL307308A (en) | Multispecific antibodies targeting BCMA | |
| CA3200847A1 (en) | Multi-specific antibodies and antibody combinations | |
| CN116234826A (zh) | Btla抗体 | |
| JP7699210B2 (ja) | Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント | |
| US20250059288A1 (en) | Antibodies targeting ccr2 | |
| TWI770619B (zh) | 對lif具有專一性的結合分子及其用途 | |
| TW202300516A (zh) | Ｐｄ—１結合蛋白及其醫藥用途 | |
| JP7846925B2 (ja) | Ｃｄ２５を標的とする抗体及びその製造方法と応用 | |
| JP7206772B2 (ja) | ヒトｇｐ１３０受容体に対するヒト化抗体 | |
| TWI773264B (zh) | 結合人ngf的抗體、其製備方法和用途 | |
| US20250376527A1 (en) | Antagonist for treating membranous nephropathy and use thereof | |
| JP2021513357A5 (https=) | ||
| JP2018153172A (ja) | インターロイキン−６ファミリーサイトカインに対するアンタゴニスト | |
| WO2023051680A1 (zh) | 针对免疫检查点的双特异性抗体 | |
| RU2025133170A (ru) | Антитело к cd40l и его применение при лечении аутоиммунных заболеваний человека | |
| WO2025140552A1 (zh) | 抑瘤素M受体β结合抗体及其用途 | |
| NZ776117B2 (en) | Antibodies to human complement factor c2b and methods of use | |
| RU2025100857A (ru) | Моноклональное антитело к tfpi и его применение | |
| WO2023284741A1 (zh) | Pd-1抗体及其用途 |